8-K: Sotera Health Reports Mixed Q1 2025 Results: Revenue Up, Net Loss Reported Due to Settlement

Sotera Health's first-quarter 2025 results show revenue growth but a net loss due to a settlement related to ethylene oxide (EO) claims.

Summary

• Sotera Health reported a 2.6% increase in net revenues for Q1 2025, reaching $255 million compared to $248 million in Q1 2024.
• On a constant currency basis, net revenues increased by 4.4%.
• The company reported a net loss of $13 million, or $0.05 per diluted share, compared to a net income of $6 million, or $0.02 per diluted share in Q1 2024; this includes a $31 million settlement related to ethylene oxide (EO) claims.
• Adjusted EBITDA increased by 8.8% to $122 million, or 11.2% on a constant currency basis.
• Adjusted EPS increased by $0.01 to $0.14 per diluted share.
• The company reaffirmed its full-year 2025 outlook, projecting net revenue growth of 4.0% 6.0% and Adjusted EBITDA growth of 4.5% 6.5%, both on a constant currency basis.
• As of March 31, 2025, Sotera Health had $2.3 billion in total debt and $304 million in cash and cash equivalents.
• The company's Net Leverage Ratio improved to 3.6x as of March 31, 2025, from 3.7x as of December 31, 2024.
• On April 30, 2025, the company closed on an amendment to its revolving credit facility that increased the facility's size by $176 million to a total of $600 million, and extended its maturity date to April 2030.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and Adjusted EBITDA increased, the net loss due to the settlement tempers the positive aspects. The reaffirmed outlook provides some reassurance.

Positives

• Sotera Health reported overall revenue growth of 2.6% in Q1 2025.
• Adjusted EBITDA saw a substantial increase of 8.8%.
• Nordion experienced significant revenue growth of 35.6%.
• The company reaffirmed its full-year 2025 outlook, indicating confidence in future performance.
• The Net Leverage Ratio improved, suggesting better financial health.
• The revolving credit facility was amended, increasing its size by $176 million to $600 million and extending the maturity date to April 2030.

Negatives

• The company reported a net loss of $13 million, primarily due to a $31 million settlement related to ethylene oxide (EO) claims.
• Nelson Labs experienced a decrease in net revenues of 9.3%.

Risks

• The company faces risks related to the availability and supply of EO and Co-60.
• Fluctuations in foreign currency exchange rates could impact financial results.
• Evolving environmental, health, and safety regulations pose ongoing challenges.
• The company is subject to litigation related to the use, emissions, and releases of EO.
• The company's significant leverage could adversely affect its ability to raise additional capital.

Future Outlook

The company reaffirms its full-year 2025 outlook, projecting net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%, both on a constant currency basis; foreign currency headwinds are expected to impact net revenues by approximately 1.25% and Adjusted EBITDA by approximately 1.50%.

Management Comments

• We are pleased to report a solid start to the year with mid-single digit revenue growth and strong double digit Adjusted EBITDA growth, on a constant currency basis, said Chairman and Chief Executive Officer, Michael B. Petras, Jr.
• We have consistently demonstrated the ability to sustain growth and navigate challenges through varying market conditions.
• Today we are reaffirming our 2025 outlook as our team remains steadfast in our mission of Safeguarding Global Health.

Industry Context

Sotera Health operates in the healthcare industry, providing sterilization solutions, lab testing, and advisory services; the results reflect the demand for these services, but also the challenges related to environmental regulations and litigation, particularly concerning ethylene oxide (EO).

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without knowing the specific growth rates and profitability metrics of Sotera Health's direct competitors.
• However, companies like Steris, Advanced Sterilization Products (ASP), and smaller testing labs could be considered peers.
• Steris has shown consistent revenue growth and profitability in the healthcare sterilization market.
• The impact of EO-related litigation and regulatory changes is a unique challenge for Sotera Health, potentially affecting its performance relative to peers.

Legal Proceedings

• The company is addressing litigation related to the use, emissions, and releases of EO from its facilities.
• A $31 million settlement was reached regarding 97 pending and threatened EO claims against Sterigenics U.S., LLC in Illinois.

Stakeholder Impact

• Shareholders are impacted by the mixed financial results, including revenue growth offset by a net loss.
• Employees are affected by the company's performance and ongoing challenges related to EO.
• Customers rely on Sotera Health's services for sterilization and lab testing, and the company's ability to navigate regulatory and legal challenges is crucial.
• Suppliers are impacted by the company's supply chain continuity, particularly for EO and Cobalt-60 (Co-60).
• Creditors are affected by the company's debt levels and ability to meet its obligations.

Next Steps

• Sotera Health management will host a conference call and live webcast to discuss the company's financial results and operating highlights at 9:00 a.m. Eastern Daylight Time today.
• Sotera Health 2025 Annual Meeting of Stockholders at 9:00 a.m. Eastern Daylight Time, May 21, 2025.
• Jefferies Global Healthcare Conference at 7:35 a.m. Eastern Daylight Time, June 4, 2025.
• Goldman Sachs 4th annual Global Healthcare Conference at 10:00 a.m. Eastern Daylight Time, June 10, 2025.

Key Dates

Keywords

Sotera Health, financial results, Q1 2025, net revenues, Adjusted EBITDA, ethylene oxide, Sterigenics, Nordion, Nelson Labs, sterilization solutions, lab testing, healthcare industry